scholarly journals Increase in Pulse Pressure Relates to Diabetes Mellitus and Low HDL Cholesterol, but Not to Hyperlipidemia in Hypertensive Patients Aged 50 Years or Older.

2002 ◽  
Vol 25 (3) ◽  
pp. 335-341 ◽  
Author(s):  
Takako MIYAGI ◽  
Hiromi MURATANI ◽  
Yorio KIMURA ◽  
Koshiro FUKIYAMA ◽  
Yuhei KAWANO ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Pulse Pressure ◽  
Hdl Cholesterol ◽  
Hypertensive Patients ◽  
Low Hdl

scholarly journals Prevalence of obesity, hypertension and metabolic abnormalities in patients receiving long term cART: a case control study from South India

2017 ◽  
Vol 6 (7) ◽  
pp. 1620
Author(s):  
Vasudeva Acharya ◽  
Govind Gangadharan
Keyword(s):  
Diabetes Mellitus ◽  
Abdominal Obesity ◽  
Hdl Cholesterol ◽  
Cardiovascular Morbidity ◽  
Metabolic Abnormalities ◽  
Significant Difference ◽  
Low Hdl ◽  
Prevalence Of Obesity ◽  
Obesity Hypertension

Background: Combination antiretroviral therapy (cART) has improved the quality of life and survival of HIV-infected individuals. However, the long term intake of these drugs is associated with multiple metabolic abnormalities eventually leading to increased risk for cardiovascular morbidity and mortality.Methods: Forty five HIV-infected individuals who are on cART having CD4+ cell count of >200 cells/mm3 for at least 2 years were recruited as cases. Age and gender matched, otherwise healthy individuals were taken as controls. Both cases and controls were compared for the prevalence of obesity, abdominal obesity, hypertension, diabetes mellitus and lipid abnormalities.Results: We found higher prevalence of obesity (33.3% vs 26.7%), abdominal obesity (33.3% vs 17.8%), hypertension (33.3% vs 20%), impaired fasting glucose (IFG) (37.7% vs 8.9%), diabetes mellitus (26.7% vs 24.4%), high total cholesterol (33.3% vs 22.2%) and low HDL cholesterol (60% vs 46.7%) among cases compared to controls. The statistically significant difference was noted only for IFG (cases = 17, 37.7%, controls = 4, 8.9%, p value = 0.002). Low HDL cholesterol was the most common metabolic abnormality found in 27 (60%) cases and 21 (46.7%) controls.Conclusions: HIV-infected individuals receiving long term cART have higher prevalence of obesity, hypertension and dysregulations in glucose and lipid metabolism compared to general population and hence, the diagnosis and management of these abnormalities is very important to prevent cardiovascular morbidity and mortality.

scholarly journals Diabeteses dyslipidaemia és atherosclerosis

2016 ◽  
Vol 157 (19) ◽  
pp. 746-752 ◽  
Author(s):  
László Márk ◽  
Győző Dani
Keyword(s):  
Diabetes Mellitus ◽  
Myocardial Infarction ◽  
High Risk ◽  
Statin Therapy ◽  
Ldl Cholesterol ◽  
Hdl Cholesterol ◽  
Small Dense Ldl ◽  
Target Values ◽  
Postprandial Triglyceride ◽  
Low Hdl

The incidence and the public health importance of diabetes mellitus are growing continuously. Despite the improvement observed in the latest years, the leading cause of morbidity and mortality of diabetics are cardiovascular diseases. The diagnosis of diabetes mellitus constitutes such a high risk as the known presence of vascular disease. Diabetic dyslipidaemia is characterised by high fasting and postprandial triglyceride levels, low HDL level, and slightly elevated LDL-cholesterol with domination of atherogenic small dense LDL. These are not independent components of the atherogenic dyslipidaemia, but are closely linked to each other. Beside the known harmful effects of low HDL and small dense LDL, recent findings confirmed the atherogenicity of the triglyceride-rich lipoproteins and their remnants. It has been shown that the key of this process is the overproduction and delayed clearance of triglyceride-rich lipoproteins in the liver. In this metabolism the lipoprotein lipase has a determining role; its function is accelerated by ApoA5 and attenuated by ApoC3. The null mutations of the ApoC3 results in a reduced risk of myocardial infarction, the loss-of-function mutation of ApoA5 was associated with a 60% elevation of triglyceride level and 2.2-times increased risk of myocardial infarction. In case of diabetes mellitus, insulin resistance, obesity, metabolic syndrome and chronic kidney disease the non-HDL-cholesterol is a better marker of the risk than the LDL-cholesterol. Its value can be calculated by subtraction of HDL-cholesterol from total cholesterol. Target values of non-HDL-cholesterol can be obtained by adding 0.8 mmol/L to the LDL-cholesterol targets (this means 3.3 mmol/L in high, and 2.6 mmol/L in very high risk patients). The drugs of first choice in the treatment of diabetic dyslipidaemia are statins. Nevertheless, it is known that even if statin therapy is optimal (treated to target), a considerable residual (lipid) risk remains. For its reduction treatment of low HDL-cholesterol and high triglyceride levels is obvious by the administration of fibrates. In addition to statin therapy, fenofibrate can be recommended. Orv. Hetil., 2016, 157(19), 746–752.

scholarly journals Acute myocardial infarction in a 17-year-old Bangladeshi boy-possibility of existence of a Bangladeshi paradox

2016 ◽  
Vol 3 (3) ◽  
pp. 62
Author(s):  
Prabir Kumar Das ◽  
F. Hossain ◽  
M.R. Karim
Keyword(s):  
Diabetes Mellitus ◽  
Risk Factors ◽  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Hdl Cholesterol ◽  
Anterior Wall ◽  
Emerging Risk ◽  
Low Hdl ◽  
Artery Disease ◽  
Conventional Risk Factors

Coronary artery disease (CAD) and acute myocardial infarction (AMI) are  diseases of older age. AMI is uncommon in young age  and rare in adolescence. A seventeen years old Bangladeshi boy developing acute anterior wall MI is described here. Risk factor analysis for CAD revealed absence of most of the conventional risk factors, like  smoking, diabetes mellitus, hypertension. An  elevated lipoprotein(a) and a low HDL cholesterol  was detected in  blood  which are emerging risk factors  of  CAD  in young Bangladeshis.

scholarly journals A Contemporary Overview of PPARα/γ Dual Agonists for the Management of Diabetic Dyslipidemia

2019 ◽  
Vol 12 (3) ◽  
pp. 195-201 ◽  
Author(s):  
Pitchai Balakumar ◽  
Nanjaian Mahadevan ◽  
Ramanathan Sambathkumar
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Resistance ◽  
Therapeutic Option ◽  
Hdl Cholesterol ◽  
High Plasma ◽  
Cholesterol Concentration ◽  
Current Status ◽  
Peroxisome Proliferator ◽  
Diabetic Dyslipidemia ◽  
Low Hdl

Background: Diabetes mellitus and concomitant dyslipidemia, being referred to as ‘diabetic dyslipidemia’, are the foremost detrimental factors documented to play a pivotal role in cardiovascular illness. Diabetic dyslipidemia is associated with insulin resistance, high plasma triglyceride levels, low HDL-cholesterol concentration and elevated small dense LDL-cholesterol particles. Maintaining an optimal glucose and lipid levels in patients afflicted with diabetic dyslipidemia could be a major task that might require a well-planned diet-management system and regular physical activity, or otherwise an intake of combined antidiabetic and antihyperlipidemic medications. Synchronized treatment which efficiently controls insulin resistance-associated diabetes mellitus and co-existing dyslipidemia could indeed be a fascinating therapeutic option in the management of diabetic dyslipidemia. Peroxisome proliferator-activated receptors α/γ (PPARα/γ) dual agonists are such kind of drugs which possess therapeutic potentials to treat diabetic dyslipidemia. Nevertheless, PPARα/γ dual agonists like muraglitazar, naveglitazar, tesaglitazar, ragaglitazar and aleglitazar have been reported to have undesirable adverse effects, and their developments have been halted at various stages. On the other hand, a recently introduced PPARα/γ dual agonist, saroglitazar is an emerging therapeutic agent of glitazar class approved in India for the management of diabetic dyslipidemia, and its treatment has been reported to be generally safe and well tolerated. Conclusion: Some additional and new compounds, at initial and preclinical stages, have been recently reported to possess PPARα/γ dual agonistic potentials with considerable therapeutic efficacy and reduced adverse profile. This review sheds light on the current status of various PPARα/γ dual agonists for the management of diabetic dyslipidemia.

scholarly journals Positive Association between Triglyceride-Rich Lipoprotein Cholesterol and Diabetes Mellitus in Hypertensive Patients

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
Wei Zhou ◽  
Yu Yu ◽  
Lingjuan Zhu ◽  
Wangsheng Fang ◽  
Yu Tao ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Healthy Lifestyle ◽  
Positive Association ◽  
Hdl Cholesterol ◽  
Study Data ◽  
Lipoprotein Cholesterol ◽  
Lipid Lowering ◽  
Hypertensive Patients ◽  
Triglyceride Rich Lipoprotein ◽  
New Strategy

Background. The association between triglyceride-rich lipoprotein cholesterol (TRL-C) and diabetes mellitus (DM) remains unclear because of limited research and data. The aim of this study was to explore the independent association between TRL-C and DM in hypertensive patients and to examine whether a healthy lifestyle would have an impact on this relationship. Methods. In this study, data from 13,721 hypertensive patients who were not treated with lipid-lowering drugs were analyzed. TRL-C was calculated from total cholesterol (TC) minus [LDL cholesterol + HDL cholesterol]. DM was defined as fasting plasma glucose of ≥7.0 mmol/L and/or self-reported history of hypoglycemic drug use. Results. After adjusting for potential confounding factors, the TRL-C was significantly positively associated with elevated DM (odds ratio (OR): 1.73 and 95% confidence interval (CI): 1.54–1.94). In subgroup analysis, a healthy lifestyle (HL) failed to modify the positive association between TRL-C and DM (HL: OR 1.93, 95%CI 1.58–2.36; non-HL: OR 1.72, 95%CI 1.50–1.98; P for interaction = 0.38). Conclusion. The results showed a positive association between TRL-C and DM in hypertensive patients. A healthy lifestyle failed to diminish the relationship between TRL-C and DM. The novel findings indicate that TRL-C might be a reliable marker of DM and may provide a new strategy for the prevention and treatment of DM.

P2646Determinants of aortic root dilatation over time in hypertensive treated patients: the Campania Salute Network

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
G Canciello ◽  
C Mancusi ◽  
R Izzo ◽  
N De Luca ◽  
B Trimarco ◽  
...  
Keyword(s):  
Aortic Root ◽  
Leading Edge ◽  
Hdl Cholesterol ◽  
Left Ventricular ◽  
Metabolic Disturbances ◽  
Hypertensive Patients ◽  
Low Hdl ◽  
Male Sex ◽  
Over Time

Abstract Background We demonstrated that aortic root (AR) dilatation assessed by standardized difference between observed and predicted values is present at baseline in about 30% of treated hypertensive patients and predicts cardiovascular (CV) events independently of left ventricular (LV) hypertrophy (LVH). Purpose We investigate whether a CV phenotype exists predicting AR dilatation during follow-up of treated hypertensive patients. Methods 5301 hypertensive treated patients (age 53±11 years, 42% women) without prevalent CV disease and with normal ejection fraction (≥50%) were studied. AR dimension was measured in the parasternal long-axis view at the level of sinus of Valsalva in end-diastole, using the leading-edge to leading-edge method at first and last available echocardiograms. The z-score of AR dimension (AOz) was generated based on the difference between observed AR and predicted AR dimension, divided by sex-specific observed SD. Results Initial AOz exhibited a normal distribution and was correlated positively with age, male sex, systolic and diastolic blood pressure (BP), BMI, fasting glucose, and glomerular filtration rate (GFR, by EPI-CKD) and negatively with pulse pressure (PP) and cholesterol (all 0.0375th percentile of the AOz distribution). Similar to baseline, initial SVi and BMI remained the most potent covariates of the final AOz (both p<0.0001), independently of significant effect of male sex, high diastolic BP, BMI, SVi, low PP, and low HDL-cholesterol. Variance inflation factor was <2 in both regression models. Figure shows initial SVi in relation with AR at follow up. Conclusions We demonstrate that both volume (SVi) and pressure loads (diastolic BP) influence AR enlargement over time, AR dilatation is predictable in male obese patients with diastolic hypertension and other metabolic disturbances.

scholarly journals Low HDL cholesterol is correlated to the acute ischemic stroke with diabetes mellitus

2014 ◽  
Vol 13 (1) ◽  
pp. 171 ◽  
Author(s):  
Yun Luo ◽  
Jingwei Li ◽  
Junfeng Zhang ◽  
Yun Xu
Keyword(s):  
Diabetes Mellitus ◽  
Ischemic Stroke ◽  
Acute Ischemic Stroke ◽  
Hdl Cholesterol ◽  
Low Hdl

scholarly journals Komponen Sindrom Metabolik sebagai Faktor Risiko Penyakit Ginjal Kronik Stadium Terminal (Studi di RSUP Dr.Kariadi dan RSUD Kota Semarang)

2018 ◽  
Vol 3 (1) ◽  
pp. 18
Author(s):  
Kartika Ikawati ◽  
Shofa Chasani ◽  
Suhartono Suhartono ◽  
Suharyo Hadisaputro ◽  
Selamat Budijitno
Keyword(s):  
Diabetes Mellitus ◽  
Risk Factors ◽  
Metabolic Syndrome ◽  
Hdl Cholesterol ◽  
Individual Characteristics ◽  
Adequate Knowledge ◽  
Low Hdl ◽  
History Of ◽  
The Individual ◽  
Metabolic Syndrome Components

Background: End Stage Renal Disease (ESRD) has been among the top ten list of non infectious diseases frequently found at RSUP dr. Kariadi and RSUD Kota Semarang. Risk factors for ESRD are metabolic syndrome components, which are having an upward trend. This study had an objective to provided an evidence of metabolic syndrome factors that became risk factors for ESRD.Method: This study applied an analytical observational method with a case control study design. The study used 90 respondents as samples, divided into two different groups: 45 respondents as case samples and 45 respondents as control samples with consecutive sampling. Variables in this study ware the individual characteristics and history of suffering from metabolic syndrome components. Data were collected by interview, medical record, and indepth interview. These data were subject to analyses using univariat, bivariate, and multivariate tests.Results: The study found the risk factors for ESRD as the followings: hypertension term of> 5 years (OR=10,89 and 95% CI=3,08-38,59; p=0,000), diabetes mellitus term of > 5 years (OR=3,84; 95% CI=1,20-12,30; p=0,023), and low HDL-cholesterol history of < 35 mg/dL(men) and < 40 mg/dL(women) with (OR=3.123, 95% CI=1.08-9.04; p=0,04). The indepth interview resulted in adequate knowledge of the respondents about the risk factors for ESRD.Conclusion: Risk factors for ESRD found during the observation were hypertension term of >5 years, diabetes mellitus term of >5 years, and low cholesterol HDL. To prevent theprogression of chronik kidney disease required strict control of metabolic syndrome.

Sign in / Sign up

Export Citation Format

Share Document